Navigation Links
Fred Hutchinson Cancer Research Center to co-lead 1 of 5 NCI-funded proteomics research centers
Date:8/22/2011

SEATTLE The National Cancer Institute today announced that a team co-led by Fred Hutchinson Cancer Research Center and The Broad Institute in Cambridge, Mass., has been selected to participate in a National Cancer Institute-funded research consortium dedicated to understanding the molecular basis of cancer . The researchers will aim to identify and analyze proteins in the blood that are associated with genetic alterations that lead to cancer. The overarching goal of the Clinical Proteomic Tumor Analysis Consortium, or CPTAC, is to improve the ability to prevent, diagnose and treat cancer.

The Hutchinson Center/Broad-led team will receive approximately $9 million in federal funding over three years with the possibility of an additional two years of funding pending scientific review mid-program.

Co-principal investigators of the Hutchinson Center/Broad team are Amanda Paulovich, M.D., Ph.D., an associate member of the Hutchinson Center's Clinical Research Division, and Steven Carr, Ph.D., director of Proteomics at the Broad Institute of MIT and Harvard. Their group is among five NCI-funded Proteome Characterization Centers nationwide that will work to define the interplay of genes and proteins on cancer development and prognosis.

This is not the first time the Paulovich and Carr laboratories have collaborated; in 2006 they, along with Leigh Anderson, Ph.D., founder and CEO of the Plasma Proteome Institute in Washington, D.C., were selected to co-lead one of five teams that received NCI funding during the first phase of the consortium, which was launched with the goal of improving success rates for developing new blood tests for cancer.

Understanding the body's protein landscape is important because proteins are the workhorses of the cell that carry out genetic instructions. Changes in the structure or abundance of proteins are associated with genetic mutations that cause diseases such as cancer.

Ultimately, the "holy grail" of proteomics the large-scale study of proteins is the discovery of protein biomarkers that could be used to create reliable and inexpensive blood tests to identify the onset and risk of a wide range of cancers and other diseases so they could be prevented or treated at the earliest possible stage, when cure rates are highest.

For the project, Paulovich, Carr and colleagues will continue their work, which harnesses a highly sensitive and targeted analytical technology multiple reaction monitoring mass spectrometry to develop assays, or tests, to measure levels of proteins found in cancer cells and patient blood. Unlike traditional mass spectrometry, which attempts to detect all proteins in a biological sample in a scattershot fashion, this technology is highly targeted, allowing researchers to calibrate the equipment to specifically look for peptides, or protein fragments, of interest, filtering out the rest as white noise.

Papers detailing the use of these technologies were published back-to-back by the Paulovich and Carr laboratories in the June 2011 issue of Nature Biotechnology.

During the second phase of consortium funding, Paulovich, Carr and colleagues throughout the network will use data and biospecimens from The Cancer Genome Atlas, or TCGA, a collaborative effort by NCI and the National Human Genome Research Institute. The CPTAC network will use proteomics to analyze cancer tissues that have also been characterized at the gene level by TCGA. The genomic and proteomic data will be combined to study the biology of the tumors, as well as to identify potential new diagnostic tests for cancer.

The other Proteome Characterization Centers are based at Pacific Northwest National Laboratory in Richland, Wash.; the University of North Carolina in Chapel Hill and Boise State University in Idaho; Johns Hopkins University in Baltimore; and Vanderbilt University in Nashville.


'/>"/>

Contact: Kristen Woodward
kwoodwar@fhcrc.org
206-667-5095
Fred Hutchinson Cancer Research Center
Source:Eurekalert

Related medicine news :

1. Hutchinson Center receives $8.2M to coordinate obesity and cancer consortium
2. Shanghai CDC and Hutchinson Center establish Shanghai Breast Health Resource Center
3. Fred Hutchinson Cancer Research Center to lead Immunotherapy Clinical Trials Network
4. NCI awards $11.5 million to Fred Hutchinson Cancer Research Center to lead breast cancer consortium
5. Fred Hutchinson Cancer Research Center scientist receives Presidential Early Career Award
6. Hutchinson Center and China CDC sign agreement for research and training collaboration
7. Hutchinson Center receives $10.24 million from NIH for Latina breast cancer research
8. 17 percent of cancer nurses unintentionally exposed to chemotherapy, U-M study finds
9. The ignored virus that causes liver cancer
10. Radioembolization improves chance of survival for liver cancer patients
11. Saffron shows promise in preventing liver cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... ... for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas of ... AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to ...
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, ... minimum wage raise to $12 an hour by 2020 and then adjusting it yearly to ... value of the minimum wage, assure the wage floor does not erode again, and make ...
(Date:6/24/2016)... ... 2016 , ... EB Medicine presented its first-ever “Issue of ... in Ponte Vedra Beach, FL. The awards honor the outstanding work of leading ... and Pediatric Emergency Medicine Practice. , “With this award, we recognize the efforts ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... The Grove Investment Group (TGIG), has initiated cultivation and processing operations at its ... Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of a complete system ...
(Date:6/24/2016)... ... , ... National recruitment firm Slone Partners is pleased to announce ... experience, as Vice President of North American Capital Sales at HTG Molecular . ... sales team in the commercialization of the HTG EdgeSeq system and associated reagents in ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, ... less invasive and more durable cerebrospinal fluid treatments, ... funding.  The Series-A funding is led by Innova ... Fund, and other private investors.  Arkis, new financing ... instrumentation and the market release of its in-licensed ...
(Date:6/23/2016)... 2016  In a startling report released today, National Safety ... lacking a comprehensive, proven plan to eliminate prescription opioid overdoses. ... how states are tackling the worst drug crisis in recorded U.S. ... Kentucky , New Mexico , ... Of the 28 failing states, three – Michigan ...
(Date:6/23/2016)... Bracket , a leading clinical trial technology ... outcomes platform, Bracket eCOA (SM) 6.0, at the 52 ... 30, 2016 in Philadelphia , Pennsylvania.  A ... product of its kind to fully integrate with RTSM, will ... 6.0 is a flexible platform for electronic clinical outcomes assessments ...
Breaking Medicine Technology: